POET Technologies Banks $400M From Single Investor as Q1 Sales Miss, Class Actions Mount

POET raises $400M from single investor to expand AI chip manufacturing, but Q1 revenue of $503K misses estimates, a key customer canceled orders, and class-action lawsuits mount.

The optics of a company sitting on $429 million in cash while generating barely half a million dollars in quarterly revenue are rarely clean. For POET Technologies, that disconnect is now the central tension as it tries to persuade investors that a massive capital injection can deliver the scale its photon?based AI chips demand — while legal challenges and a lost customer threaten to undermine the entire narrative.

A premium?priced placement with a single backer

On May 18, POET closed a registered direct offering that raised gross proceeds of $400 million. The deal was notable for its structure: a single institutional investor took down the entire transaction, purchasing roughly 19 million units at $21.00 apiece. Each unit consisted of one common share and a warrant exercisable at $26.25, valid for three years. A beneficial ownership cap of 9.99% was also written into the terms.

Net proceeds come to about $399.7 million. Management plans to funnel that capital into a ten?fold expansion of wafer and optical engine manufacturing capacity by 2027, with additional funds earmarked for R&D, its light?source business, potential acquisitions, and working capital. The aggressive scaling target signals a bet that demand from AI data centers will materialize at the pace POET needs.

Quarterly results that fell short

The company’s first?quarter numbers, however, did little to validate that optimism. Revenue came in at just $503,389 — a fraction of the $2.2 million analysts had expected, though a sharp increase from the $166,760 reported a year earlier. The net loss per share of $0.08 was wider than the $0.05 consensus estimate, and operating expenses reached $18.37 million. Cash burn from operations stood at $8.8 million.

The balance sheet is undeniably strong — quarter?end cash of $429.1 million buys time — but the market’s reaction reflected a broader impatience with the pace of commercialization. POET shares closed at $14.21 on May 18, down 11.02% on the day, after swinging between $13.33 and $17.17. Just days earlier, the stock had touched a 52?week high of $20.81.

A canceled order and a wave of class actions

The stock’s decline is not solely about the revenue miss. Late April saw a 45% crash after news emerged that Celestial AI, a subsidiary of Marvell, had canceled all outstanding orders. The trigger, according to reports, was a leak by POET management that allegedly disclosed confidential information.

That leak has now spawned multiple class?action lawsuits. Investors accuse POET of making misrepresentations about its U.S. tax status, potentially exposing American shareholders to adverse consequences. A lead?plaintiff deadline has been set for June 29, 2026. Separately, short seller Night Market Research has questioned the transparency of certain partnerships and the company’s order backlog.

A bright spot in the order book

Not all customer news is negative. POET recently signed a strategic supply agreement with Lumilens that includes an initial $50 million order. The longer?term potential of that partnership could reach $500 million. It is a significant win, but one that will take years to flow through the income statement.

Management reshuffles and factory expansion

To handle the production ramp, POET is restructuring its leadership. CFO Thomas Mika has announced his retirement after a decade with the company; a search for his successor is under way. Sandeep Kumar has been appointed chief operating officer, tasked with overseeing the manufacturing scale?up.

On the ground, POET now employs more than 115 people globally. Its Singapore lab has been nearly tripled in size, and the company has secured roughly 20,000 square feet of assembly space in Malaysia to support mass production. The infrastructure build?out is unmistakably ambitious — but whether it can be matched by a commensurate rise in revenue remains the market’s defining question.